PKLR
Pyruvate kinase PKLR
As of the edition of 20 October 2026, PKLR (pyruvate kinase PKLR, UniProt P30613) has 2 drugs tested at it and 3 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P30613
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 79
- Disease areas
- Blood and lymph; Inherited and neonatal; Nutrition and metabolism; Digestive system; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 43
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Mitapivat | Marketed | Phase 4 | Ends 2038 |
| Etavopivat | Active | Phase 3 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Engaged | 2 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Agios Pharmaceuticals | Route B |
The other 2 companies at PKLR
In the product3 companies in all; 2 are not named here, and no score is.
See the 3 companies at PKLR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.